Patent · US Active

Compounds

US8691826B2 · kind B2 · utility

4Cited by
1References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 13, 2012
Grant dateApr 8, 2014
Priority date—
Expiry dateSep 13, 2032

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P17/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of formula (I):are useful as inhibitors of human neutrophil elastase.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.